OXi4503 combretastatin A1 di-phosphate: Phase Ib/IIa started

OxiGene began an open-label, dose-escalation, Australian Phase Ib/Ila trial to evaluate IV OXi4503 on days 1, 8 and 15 of a 28-day cycle in about 63 patients with primary hepatocellular carcinoma (HCC...